Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for the treatment of Parkinson’s disease, among others.
Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized molecular glue degraders comprising cereblon (CRBN) binding agents and protein degradation moieties reported to be useful for the treatment of cancer, infections, autoimmune diseases, anemia, transplant rejection, diabetes, cardiovascular disorders and inflammatory disorders, among others.
Blueprint Medicines Corp. has disclosed PROTAC compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 4 (CDK4)-targeting moiety potentially useful for the treatment of cancer.
In an effort to identify stronger and safer α-glucosidase inhibitors, researchers at the Chinese Academy of Sciences prepared a series of diarylpentane derivatives, the most promising of which, [I], reversibly inhibited α-glucosidase with an IC50 of 18 µM.
In an effort to develop more effective estrogen receptor α (ERα) inhibitors, researchers at Nanjing University of Chinese Medicine and collaborators aimed to develop a proteolysis targeting chimera (PROTAC) against the receptor.
Researchers from Northeast Agricultural University and Jiangsu Kanion Pharmaceutical Co. Ltd. aimed to improve the oncolytic effect of existing Newcastle disease virus (NDV) vectors using engineering strategies to accelerate their clinical translation.
Researchers from Tango Therapeutics Inc. presented preclinical efficacy data on TNG-456, a selective MTA-cooperative PRMT5 inhibitor under development for the treatment of glioma and other tumors that frequently metastasize to the brain, such as non-small-cell lung cancer.
SK Biopharmaceuticals Co. Ltd. has signed a license agreement with the Wisconsin Alumni Research Foundation (WARF) to acquire rights to WARF’s WT-7695, a preclinical-stage radiopharmaceutical therapy candidate developed in collaboration with the University of Wisconsin-Madison.
RSS
